D. Sidransky

Molecular Biology · 2000–2017

A researcher in the Science corpus: 12 papers; trusts 3 researchers and is trusted by 16 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 18 citations into it; #2,236 of 17,773 by trust here, #5,137 by citations
• Oncology — 17 citations into it; #85 of 1,698 by trust here, #993 by citations

Whom D. Sidransky trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. S. Baylin
2. J. Herman

Who trusts D. Sidransky overall

1. Allan Balmain
2. Yaakov Benenson
3. Peter A. Jones
4. Jean-Pierre Issa
5. Joe W. Gray
6. Bert Vogelstein
7. Binyamin Gil
8. J. Ludwig
9. Bruce A. J. Ponder
10. S. Baylin

Papers from D. Sidransky's perspective

Ordered by how strongly the researchers D. Sidransky trusts endorse each paper. Same corpus, a different order for every researcher.

1. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. (Science)
2. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. (Trends in Genetics)
3. Molecular pathogenesis and mechanisms of thyroid cancer (Nature Reviews. Cancer)
4. Nonparametric Estimation from Incomplete Observations
5. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status (Nature)
6. BRAF mutation in thyroid cancer. (Endocrine-Related Cancer)
7. Cochrane review on screening for breast cancer with mammography. (The Lancet)
8. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. (Endocrine reviews)
9. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. (Journal of Clinical Endocrinology and Metabolism)
10. Systematic variation in gene expression patterns in human cancer cell lines (Nature Genetics)

Their papers

• BRAF mutation in papillary thyroid carcinoma. (2003) — 894 citations
• Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. (2000) — 838 citations
• Emerging molecular markers of cancer (2002) — 672 citations
• Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 (2011) — 1,798 citations
• TP53 mutations and survival in squamous-cell carcinoma of the head and neck. (2007) — 780 citations
• KRAS-variant is a biomarker of cetuximab response potentially through altered immunity in head and neck cancer: Re-analysis of NRG Oncology/RTOG 0522 (2017)
• Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer (2013) — 903 citations
• BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. (2005) — 1,008 citations
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. (2003) — 899 citations
• Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. (2002) — 656 citations
• Head and neck cancer. (2001) — 675 citations
• Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. (2000) — 3,171 citations